(60) Impact of Donor Specific Antibodies in Cardiac Transplant Recipients after Acute Covid-19
Donor specific antibodies (DSA) are known to be associated with increased mortality following heart transplant (HT). Despite the high overall burden of disease from novel coronavirus (COVID-19) among HT recipients, little is known about the subsequent development of de novo or increased DSA (diDSA)...
Gespeichert in:
| Veröffentlicht in: | The Journal of heart and lung transplantation 2023-04, Vol.42 (4), p.S36-S36 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S36 |
|---|---|
| container_issue | 4 |
| container_start_page | S36 |
| container_title | The Journal of heart and lung transplantation |
| container_volume | 42 |
| creator | Martissa, J.A. Gregoski, M.J. Houston, B. Kilic, A. Celia, A. Shore, S. Tamas, A. Maharaj, V. Agdamag, A.C. Vorovich, E. Farina, L.A. Vidula, H. Sampath, R. Hsiao, S. Alexander, K. Jamil, A. Birati, E. Chaudhry, S. Patel, A. Tedford, R.J. Genuardi, M.V. |
| description | Donor specific antibodies (DSA) are known to be associated with increased mortality following heart transplant (HT). Despite the high overall burden of disease from novel coronavirus (COVID-19) among HT recipients, little is known about the subsequent development of de novo or increased DSA (diDSA) in COVID-19 survivors.
We performed a retrospective analysis at 8 large centers of HT recipients diagnosed with COVID-19 between 3/1/2020 and 3/31/2021. Acting on anecdotal reports, we began checking DSA approximately 3, 6, and 12 months after acute COVID-19 as standard of care. Incidence of diDSA, defined as an increase in MFI by >2500, was determined. Treatment of acute cellular rejection (ACR) and antibody mediated rejection was recorded.
Of 380 HT patients who developed COVID-19, 191 (70% male) had DSA data available by study end-date. A total of 5% developed diDSA by 3 months (11/191), 10% by 6 months (17/172) and 18% by 12 months (24/131). The median time for development of diDSA was 144 days. Patients with pre-existing DSA had a significantly increased incidence of diDSA compared to those without pre-existing DSA (15/32 vs 9/159, p |
| doi_str_mv | 10.1016/j.healun.2023.02.076 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10068036</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1053249823001183</els_id><sourcerecordid>S1053249823001183</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2026-f29ddf7290312a89f70d611fa1c281d11e95e82a6df69ab35b949b36283af0213</originalsourceid><addsrcrecordid>eNp9kElLBDEQhRtRcP0HHnLUQ7dVyXS6c1GGcRsQBJerIZ1FM8x0mqRnwH9vZETw4qkK6r3Hq68oThEqBOQXi-rDquW6ryhQVgGtoOE7xQHWdVMyxGY371Czkk5Eu18cprQAyMqaHhRvZxzOyXw1KD2S4Mh16EMkz4PV3nlNpv3ou2C8TcT3ZKai8UqTl6j6NCxVP5KnLBy87cdElBttJFO9Hi2ZhY03JYrjYs-pZbInP_OoeL29eZndlw-Pd_PZ9KHUuTIvHRXGuIYKYEhVK1wDhiM6hZq2aBCtqG1LFTeOC9WxuhMT0TFOW6YcUGRHxdU2d1h3K2t0LhTVUg7Rr1T8lEF5-ffS-w_5HjYSAXgLjOeEyTZBx5BStO7XjCC_KcuF3FKW35QlUJkpZ9vl1mbzdxtvo0w649DW-Gj1KE3w_wd8AVpYh7I</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>(60) Impact of Donor Specific Antibodies in Cardiac Transplant Recipients after Acute Covid-19</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Martissa, J.A. ; Gregoski, M.J. ; Houston, B. ; Kilic, A. ; Celia, A. ; Shore, S. ; Tamas, A. ; Maharaj, V. ; Agdamag, A.C. ; Vorovich, E. ; Farina, L.A. ; Vidula, H. ; Sampath, R. ; Hsiao, S. ; Alexander, K. ; Jamil, A. ; Birati, E. ; Chaudhry, S. ; Patel, A. ; Tedford, R.J. ; Genuardi, M.V.</creator><creatorcontrib>Martissa, J.A. ; Gregoski, M.J. ; Houston, B. ; Kilic, A. ; Celia, A. ; Shore, S. ; Tamas, A. ; Maharaj, V. ; Agdamag, A.C. ; Vorovich, E. ; Farina, L.A. ; Vidula, H. ; Sampath, R. ; Hsiao, S. ; Alexander, K. ; Jamil, A. ; Birati, E. ; Chaudhry, S. ; Patel, A. ; Tedford, R.J. ; Genuardi, M.V.</creatorcontrib><description>Donor specific antibodies (DSA) are known to be associated with increased mortality following heart transplant (HT). Despite the high overall burden of disease from novel coronavirus (COVID-19) among HT recipients, little is known about the subsequent development of de novo or increased DSA (diDSA) in COVID-19 survivors.
We performed a retrospective analysis at 8 large centers of HT recipients diagnosed with COVID-19 between 3/1/2020 and 3/31/2021. Acting on anecdotal reports, we began checking DSA approximately 3, 6, and 12 months after acute COVID-19 as standard of care. Incidence of diDSA, defined as an increase in MFI by >2500, was determined. Treatment of acute cellular rejection (ACR) and antibody mediated rejection was recorded.
Of 380 HT patients who developed COVID-19, 191 (70% male) had DSA data available by study end-date. A total of 5% developed diDSA by 3 months (11/191), 10% by 6 months (17/172) and 18% by 12 months (24/131). The median time for development of diDSA was 144 days. Patients with pre-existing DSA had a significantly increased incidence of diDSA compared to those without pre-existing DSA (15/32 vs 9/159, p<0.001). There was no difference in diDSA between patients who had immunosuppression reduced during acute COVID-19 and those who did not (6/47 vs 17/107, p=0.890). Compared to those without diDSA, there was a significant increase in the incidence of ACR (ISHLT grade ≥2R) in the year following infection in those with diDSA (3/165 vs 4/24, p=0.006).
This study demonstrates a high incidence of diDSA (18%) at 12 months among HT recipients after COVID-19. In addition, diDSA was more common among those with pre-existing DSA, and diDSA was associated with higher incidence of ACR.</description><identifier>ISSN: 1053-2498</identifier><identifier>EISSN: 1557-3117</identifier><identifier>DOI: 10.1016/j.healun.2023.02.076</identifier><language>eng</language><publisher>Elsevier Inc</publisher><subject>60</subject><ispartof>The Journal of heart and lung transplantation, 2023-04, Vol.42 (4), p.S36-S36</ispartof><rights>2023</rights><rights>Copyright © 2023 Published by Elsevier Inc. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.healun.2023.02.076$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids></links><search><creatorcontrib>Martissa, J.A.</creatorcontrib><creatorcontrib>Gregoski, M.J.</creatorcontrib><creatorcontrib>Houston, B.</creatorcontrib><creatorcontrib>Kilic, A.</creatorcontrib><creatorcontrib>Celia, A.</creatorcontrib><creatorcontrib>Shore, S.</creatorcontrib><creatorcontrib>Tamas, A.</creatorcontrib><creatorcontrib>Maharaj, V.</creatorcontrib><creatorcontrib>Agdamag, A.C.</creatorcontrib><creatorcontrib>Vorovich, E.</creatorcontrib><creatorcontrib>Farina, L.A.</creatorcontrib><creatorcontrib>Vidula, H.</creatorcontrib><creatorcontrib>Sampath, R.</creatorcontrib><creatorcontrib>Hsiao, S.</creatorcontrib><creatorcontrib>Alexander, K.</creatorcontrib><creatorcontrib>Jamil, A.</creatorcontrib><creatorcontrib>Birati, E.</creatorcontrib><creatorcontrib>Chaudhry, S.</creatorcontrib><creatorcontrib>Patel, A.</creatorcontrib><creatorcontrib>Tedford, R.J.</creatorcontrib><creatorcontrib>Genuardi, M.V.</creatorcontrib><title>(60) Impact of Donor Specific Antibodies in Cardiac Transplant Recipients after Acute Covid-19</title><title>The Journal of heart and lung transplantation</title><description>Donor specific antibodies (DSA) are known to be associated with increased mortality following heart transplant (HT). Despite the high overall burden of disease from novel coronavirus (COVID-19) among HT recipients, little is known about the subsequent development of de novo or increased DSA (diDSA) in COVID-19 survivors.
We performed a retrospective analysis at 8 large centers of HT recipients diagnosed with COVID-19 between 3/1/2020 and 3/31/2021. Acting on anecdotal reports, we began checking DSA approximately 3, 6, and 12 months after acute COVID-19 as standard of care. Incidence of diDSA, defined as an increase in MFI by >2500, was determined. Treatment of acute cellular rejection (ACR) and antibody mediated rejection was recorded.
Of 380 HT patients who developed COVID-19, 191 (70% male) had DSA data available by study end-date. A total of 5% developed diDSA by 3 months (11/191), 10% by 6 months (17/172) and 18% by 12 months (24/131). The median time for development of diDSA was 144 days. Patients with pre-existing DSA had a significantly increased incidence of diDSA compared to those without pre-existing DSA (15/32 vs 9/159, p<0.001). There was no difference in diDSA between patients who had immunosuppression reduced during acute COVID-19 and those who did not (6/47 vs 17/107, p=0.890). Compared to those without diDSA, there was a significant increase in the incidence of ACR (ISHLT grade ≥2R) in the year following infection in those with diDSA (3/165 vs 4/24, p=0.006).
This study demonstrates a high incidence of diDSA (18%) at 12 months among HT recipients after COVID-19. In addition, diDSA was more common among those with pre-existing DSA, and diDSA was associated with higher incidence of ACR.</description><subject>60</subject><issn>1053-2498</issn><issn>1557-3117</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kElLBDEQhRtRcP0HHnLUQ7dVyXS6c1GGcRsQBJerIZ1FM8x0mqRnwH9vZETw4qkK6r3Hq68oThEqBOQXi-rDquW6ryhQVgGtoOE7xQHWdVMyxGY371Czkk5Eu18cprQAyMqaHhRvZxzOyXw1KD2S4Mh16EMkz4PV3nlNpv3ou2C8TcT3ZKai8UqTl6j6NCxVP5KnLBy87cdElBttJFO9Hi2ZhY03JYrjYs-pZbInP_OoeL29eZndlw-Pd_PZ9KHUuTIvHRXGuIYKYEhVK1wDhiM6hZq2aBCtqG1LFTeOC9WxuhMT0TFOW6YcUGRHxdU2d1h3K2t0LhTVUg7Rr1T8lEF5-ffS-w_5HjYSAXgLjOeEyTZBx5BStO7XjCC_KcuF3FKW35QlUJkpZ9vl1mbzdxtvo0w649DW-Gj1KE3w_wd8AVpYh7I</recordid><startdate>202304</startdate><enddate>202304</enddate><creator>Martissa, J.A.</creator><creator>Gregoski, M.J.</creator><creator>Houston, B.</creator><creator>Kilic, A.</creator><creator>Celia, A.</creator><creator>Shore, S.</creator><creator>Tamas, A.</creator><creator>Maharaj, V.</creator><creator>Agdamag, A.C.</creator><creator>Vorovich, E.</creator><creator>Farina, L.A.</creator><creator>Vidula, H.</creator><creator>Sampath, R.</creator><creator>Hsiao, S.</creator><creator>Alexander, K.</creator><creator>Jamil, A.</creator><creator>Birati, E.</creator><creator>Chaudhry, S.</creator><creator>Patel, A.</creator><creator>Tedford, R.J.</creator><creator>Genuardi, M.V.</creator><general>Elsevier Inc</general><general>Published by Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>202304</creationdate><title>(60) Impact of Donor Specific Antibodies in Cardiac Transplant Recipients after Acute Covid-19</title><author>Martissa, J.A. ; Gregoski, M.J. ; Houston, B. ; Kilic, A. ; Celia, A. ; Shore, S. ; Tamas, A. ; Maharaj, V. ; Agdamag, A.C. ; Vorovich, E. ; Farina, L.A. ; Vidula, H. ; Sampath, R. ; Hsiao, S. ; Alexander, K. ; Jamil, A. ; Birati, E. ; Chaudhry, S. ; Patel, A. ; Tedford, R.J. ; Genuardi, M.V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2026-f29ddf7290312a89f70d611fa1c281d11e95e82a6df69ab35b949b36283af0213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>60</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Martissa, J.A.</creatorcontrib><creatorcontrib>Gregoski, M.J.</creatorcontrib><creatorcontrib>Houston, B.</creatorcontrib><creatorcontrib>Kilic, A.</creatorcontrib><creatorcontrib>Celia, A.</creatorcontrib><creatorcontrib>Shore, S.</creatorcontrib><creatorcontrib>Tamas, A.</creatorcontrib><creatorcontrib>Maharaj, V.</creatorcontrib><creatorcontrib>Agdamag, A.C.</creatorcontrib><creatorcontrib>Vorovich, E.</creatorcontrib><creatorcontrib>Farina, L.A.</creatorcontrib><creatorcontrib>Vidula, H.</creatorcontrib><creatorcontrib>Sampath, R.</creatorcontrib><creatorcontrib>Hsiao, S.</creatorcontrib><creatorcontrib>Alexander, K.</creatorcontrib><creatorcontrib>Jamil, A.</creatorcontrib><creatorcontrib>Birati, E.</creatorcontrib><creatorcontrib>Chaudhry, S.</creatorcontrib><creatorcontrib>Patel, A.</creatorcontrib><creatorcontrib>Tedford, R.J.</creatorcontrib><creatorcontrib>Genuardi, M.V.</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of heart and lung transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Martissa, J.A.</au><au>Gregoski, M.J.</au><au>Houston, B.</au><au>Kilic, A.</au><au>Celia, A.</au><au>Shore, S.</au><au>Tamas, A.</au><au>Maharaj, V.</au><au>Agdamag, A.C.</au><au>Vorovich, E.</au><au>Farina, L.A.</au><au>Vidula, H.</au><au>Sampath, R.</au><au>Hsiao, S.</au><au>Alexander, K.</au><au>Jamil, A.</au><au>Birati, E.</au><au>Chaudhry, S.</au><au>Patel, A.</au><au>Tedford, R.J.</au><au>Genuardi, M.V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>(60) Impact of Donor Specific Antibodies in Cardiac Transplant Recipients after Acute Covid-19</atitle><jtitle>The Journal of heart and lung transplantation</jtitle><date>2023-04</date><risdate>2023</risdate><volume>42</volume><issue>4</issue><spage>S36</spage><epage>S36</epage><pages>S36-S36</pages><issn>1053-2498</issn><eissn>1557-3117</eissn><abstract>Donor specific antibodies (DSA) are known to be associated with increased mortality following heart transplant (HT). Despite the high overall burden of disease from novel coronavirus (COVID-19) among HT recipients, little is known about the subsequent development of de novo or increased DSA (diDSA) in COVID-19 survivors.
We performed a retrospective analysis at 8 large centers of HT recipients diagnosed with COVID-19 between 3/1/2020 and 3/31/2021. Acting on anecdotal reports, we began checking DSA approximately 3, 6, and 12 months after acute COVID-19 as standard of care. Incidence of diDSA, defined as an increase in MFI by >2500, was determined. Treatment of acute cellular rejection (ACR) and antibody mediated rejection was recorded.
Of 380 HT patients who developed COVID-19, 191 (70% male) had DSA data available by study end-date. A total of 5% developed diDSA by 3 months (11/191), 10% by 6 months (17/172) and 18% by 12 months (24/131). The median time for development of diDSA was 144 days. Patients with pre-existing DSA had a significantly increased incidence of diDSA compared to those without pre-existing DSA (15/32 vs 9/159, p<0.001). There was no difference in diDSA between patients who had immunosuppression reduced during acute COVID-19 and those who did not (6/47 vs 17/107, p=0.890). Compared to those without diDSA, there was a significant increase in the incidence of ACR (ISHLT grade ≥2R) in the year following infection in those with diDSA (3/165 vs 4/24, p=0.006).
This study demonstrates a high incidence of diDSA (18%) at 12 months among HT recipients after COVID-19. In addition, diDSA was more common among those with pre-existing DSA, and diDSA was associated with higher incidence of ACR.</abstract><pub>Elsevier Inc</pub><doi>10.1016/j.healun.2023.02.076</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1053-2498 |
| ispartof | The Journal of heart and lung transplantation, 2023-04, Vol.42 (4), p.S36-S36 |
| issn | 1053-2498 1557-3117 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10068036 |
| source | Elsevier ScienceDirect Journals Complete |
| subjects | 60 |
| title | (60) Impact of Donor Specific Antibodies in Cardiac Transplant Recipients after Acute Covid-19 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T08%3A09%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=(60)%20Impact%20of%20Donor%20Specific%20Antibodies%20in%20Cardiac%20Transplant%20Recipients%20after%20Acute%20Covid-19&rft.jtitle=The%20Journal%20of%20heart%20and%20lung%20transplantation&rft.au=Martissa,%20J.A.&rft.date=2023-04&rft.volume=42&rft.issue=4&rft.spage=S36&rft.epage=S36&rft.pages=S36-S36&rft.issn=1053-2498&rft.eissn=1557-3117&rft_id=info:doi/10.1016/j.healun.2023.02.076&rft_dat=%3Celsevier_pubme%3ES1053249823001183%3C/elsevier_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S1053249823001183&rfr_iscdi=true |